Table Of Content

National Institute for Clinical Excellence Compilation Summary of Guidance issued to the NHS in England and Wales Issue7 (@YKea) oil- 1 4010): j e l u e J O‘ ep sa Ue p ! i e pb a e i is ni jp| d 1 ne a q nJ sop s i iUn Oo uEy oss N! eOs lqu i n u d p wUe oas g o u |d ! J0 o9 s ¢Uiy| 9Oj pgU uoO eu es zp} giU ' J a ns S OJ 2U seb WS H a bp N 22 Ja edenje] N} I ssS I} XJ Uo i au Z F J}} S a U oAp ] /e e Joue [EIIUWA Ue u Sst UOII/DLVd S| eEY usAi ZE da 16FOIneu N s 4Ne | MONA 22503547917 Compilation Summary of Guidance issued to the NHS in England and Wales Issue / October 2003 The Guidance in this document is written in the following context This Guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to take it fully into account when exercising their clinical judgment. This Guidance does not, however, override the individual responsibility of health professionals to make appro- priate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. National Institute for Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA Web: www.nice.org.uk ISSN: 1473-3730 Published by the National Institute for Clinical Excellence, October 2003 Order ref: NO339 © National Institute for Clinical Excellence 2003. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute. For permissions contact: Corporate Affairs Director National Institute for Clinical Excellence MidCity Place, 71 High Holborn, London WC1V 6NA. Contents Acknowledgements 5 Introduction 6 New Guidance /7 How to use this document 9 Obtaining further information 10 Guidance issued eBehavioural 11 eCancer 15 e Cardiovascular 31 e Central nervous system 75 e Dental, oral and facial 79 eEar, nose andthroat 82 e Endocrine and metabolic 85 eEye 119 ¢ Gastrointestinal 121 e Gynaecology, pregnancy and birth 126 ° Infections and infectious diseases 174 e|njuries and accidents 192 ° Mental health 222 e Musculo-skeletal 251 e Nutritional disorders and weight control 260 e Renal and urinary 265 © Respiratory 269 e Skin disorders and wounds 272 e Miscellaneous 284 Appendices Appendix A: Forward work plans 303 Appendix B: Appraisals Committee 311 Appendix C: Guideline Review Panels 316 Appendix D: Interventional Procedures Advisory Committee 320 Appendix E: Technology Appraisal Process—Summary 322 Appendix F: Clinical Guidelines Development Process—Summary 325 Appendix G: Interventional Procedures Process — Summary 329 Appendix H: Ordering information 332 Index 350 Acknowledgements The development of NICE guidance relies on the time and commitment of those with whom the Institute works. The Institute wishes to acknowledge the contribution of the members of the Appraisal Committee, the Guidelines Advisory Committee, the Partners Council, the academic teams, the national patient/carer organisations and individual manufacturers. In addition, the Institute acknowledges the support, help, advice and commitment of a wide range of health professionals and their representative groups, including the Royal Colleges, numerous professional associations and societies and of course the wider NHS. Introduction The National Institute for Clinical Excellence (the Institute) is part of the NHS. It is a Special Health Authority and it provides guidance for the NHS and patients on medicines, medical equipment and clinical procedures based on evidence of both clinical and cost effectiveness. The Institute has been described as a virtual network. It has 60 full time employees and works with patient/carer organisations, NHS R&D manufacturers, doctors, nurses, pharmacists, academics and other health professionals in England and Wales to prepare its guidance. Full details on the Institute and its work are available on the NICE web site (www.nice.org.uk). New Guidance @ Tare) Csi lel) acest Antenatal care: routine care for the healthy pregnant woman 127 Chronic heart failure - Management of chronic heart failure in adults in primary and secondary care 32 Infection control — Prevention of healthcare-associated infection in primary and community care 175 Preoperative tests — The use of routine preoperative tests for elective surgery 285 Pressure ulcer prevention — Pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in primary and secondary care 274 Triage, assessment, investigation and early management of head injury in infants, children and adults 193 Interventional Procedures — Balloon thermal endometrial ablation 151 Coblation tonsillectomy 83 Coil embolisation of ruptured intracranial aneurysms 62 Islet cell transplantation 91 Laparoscopic radical prostatectomy 20 Microwave endometrial ablation 170 Minimally invasive placement of pectus bar 258 Percutaneous vertebroplasty 259 Radiofrequency ablation of hepatocellular carcinoma 24 Radiofrequency ablation of varicose veins 73 Sacral nerve stimulation for faecal incontinence 125 Sacral nerve stimulation for urge incontinence 267 Stent-graft placement in abdominal aortic aneurysm 73 Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife 80 Transurethral electrovapourisation of prostate (TEVAP) 268 Transurethral radiofrequency needle ablation of prostate (TUNA) 268 Uterine artery embolisation for fibroids 172 Technology Appraisals Capecitabine for the treatment of locally advanced or metastatic breast cancer 16 Capecitabine and tegafur with uracil for metastatic colorectal cancer 16 Glitazones for the treatment of type 2 diabetes 87 Human growth hormone (somatropin) in adults with growth hormone deficiency 88 Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar! 250 Oseltamivir and amantadine for the prophylaxis of influenza 188 Photodynamic therapy for age-related macular degeneration 120 Rituximab for aggressive non Hodgkin’s lymphoma 25